Detalhe da pesquisa
1.
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
J Infect Dis
; 227(7): 838-849, 2023 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35668700
2.
Lymphogranuloma venereum.
CMAJ
; 193(49): E1889, 2021 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903592
3.
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Viruses
; 16(5)2024 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38793543
4.
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
AIDS
; 37(5): 709-721, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545783
5.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
NPJ Vaccines
; 7(1): 28, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35228535
6.
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
medRxiv
; 2022 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35350205
7.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
medRxiv
; 2021 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671779